[Therapy of arterial hypertension with verapamil hydrochloride in patients after myocardial revascularization].
Verapamil hydrochloride, a calcium blocker from a group of phenyl alkylamines, was tested for its effect on central hemodynamics (CH) and blood oxygen-transporting function (BOTF) in 14 patients with arterial hypertension after surgical myocardial revascularization. CH and BOTF were studied by using a Swan-Hanz catheter and directly measuring blood pressure (BP). There was a significant reduction in BPmean, total peripheral vascular resistance index, left ventricular stroke outcome index, and oxygen delivery index. Verapamil in an average dose of 80.4 +/- 18.02 mg at the injection rate of 24.6 +/- 3.9 micrograms/kg/min was shown to make BPmean normal 16.8 +/- 6.35 min later. The agent is comparable with other calcium blockers, such as nifedipine and isradipine in its action on CH and BOTF, as well as in its efficiency and safety.
Matiunin
A V
AV
Nikiforov
Iu V
IuV
Babaev
O V
OV
D000136:Acid-Base Equilibrium / Q000187:drug effects; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009204:Myocardial Revascularization; D011183:Postoperative Complications; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014700:Verapamil